Endoglin mRNA (ENG mRNA) (ENG mRNA)

Endoglin (ENG) mRNA encodes a type I transmembrane glycoprotein that serves as a crucial co-receptor for the transforming factor-beta (TGF-beta) signaling pathway [UniProt, P17813]. It is predominantly expressed on the surface of proliferating endothelial cells and plays a vital role in angiogenesis, vascular remodeling, and maintaining endothelial integrity [NCBI Gene, 2022]. In oncology, ENG is frequently overexpressed in the tumor neovasculature, making its mRNA a potential target for silencing strategies to inhibit tumor-induced angiogenesis [PubMed, 25663131]. Mutations in the ENG gene are the primary cause of Hereditary Hemorrhagic Telangiectasia type 1 (HHT1), a condition characterized by vascular malformations [PubMed, 10544127]. Therapeutic approaches targeting ENG mRNA, such as siRNA or antisense oligonucleotides, aim to modulate its expression in conditions like cancer or preeclampsia, where dysregulated Endoglin levels contribute to pathogenesis [PubMed, 21814185]. While most clinical efforts have focused on monoclonal antibodies like carotuximab (TRC105) against the protein, mRNA-directed therapies offer a method to downregulate all isoforms of the protein at the source [ClinicalTrials.gov, NCT01090765].

Other names

CD105 mRNAHHT1 mRNAORW1 mRNAEND mRNA

RNA interference (RNAi) or antisense-mediated degradation to reduce Endoglin protein expression [PubMed, 25663131].